Wall Street analyst estimates for Baxter International Inc. (BAX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution.
Consensus price target
$23.60 (-7 % vs price $25.49)
between $20.00 and $28.00 · 4 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $11.7B | $11.7B – $11.7B | $2.09 | 9 |
| 2027E | $12.0B | $11.9B – $12.0B | $2.04 | 9 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 15 |
| Hold | 20 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 36 |
| Avg rating (−2 sell to +2 buy) | 0.39 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-11 | $0.60 | ||
| 2026-10-29 | $0.58 | $0.52 | +12.0% |
| 2026-07-30 | $0.56 | $0.37 | +52.8% |
| 2026-04-30 | $0.36 | $0.31 | +15.8% |
| 2026-02-12 | $0.44 | $0.53 | -17.0% |
| 2025-10-30 | $0.69 | $0.60 | +15.0% |
| 2025-07-31 | $0.59 | $0.60 | -1.7% |
| 2025-05-01 | $0.55 | $0.48 | +13.8% |
Valuation Ratios
| Price / Book | 1.93 |
| Dividend Yield | 0.17% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.16B | $10.58B | $11.10B | $11.36B | $11.67B | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B |
| Cost of Revenue | $6.05B | $6.11B | $6.34B | $6.60B | $7.09B | $7.43B | $6.51B | $6.21B | $6.65B | $7.87B |
| Gross Profit | $4.12B | $4.47B | $4.76B | $4.76B | $4.59B | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B |
| Research & Development | $646.0M | $615.0M | $654.0M | $595.0M | $521.0M | $531.0M | $450.0M | $518.0M | $590.0M | $518.0M |
| Selling, General & Admin | $2.73B | $2.63B | $2.62B | $2.54B | $2.47B | $2.85B | $3.10B | $2.95B | $2.97B | $2.89B |
| Operating Expenses | $3.37B | $3.19B | $3.17B | $2.99B | $2.97B | $3.37B | $6.39B | $3.44B | $3.97B | $3.69B |
| Operating Income | $745.0M | $1.29B | $1.58B | $1.77B | $1.62B | $1.35B | -$2.85B | $707.0M | $14.0M | -$308.0M |
| EBITDA | $5.84B | $1.94B | $2.48B | $1.87B | $2.27B | $2.19B | -$1.76B | $1.73B | $1.12B | $766.0M |
| Interest Expense | $89.0M | $85.0M | $93.0M | $111.0M | $153.0M | $207.0M | $413.0M | $508.0M | $408.0M | $290.0M |
| Pre-tax Income | $4.95B | $1.10B | $1.62B | $970.0M | $1.29B | $1.12B | -$3.25B | $242.0M | -$289.0M | -$505.0M |
| Income Tax | -$12.0M | $491.0M | $65.0M | -$41.0M | $182.0M | $83.0M | -$135.0M | $61.0M | $37.0M | $395.0M |
| Net Income | $4.96B | $602.0M | $1.55B | $1.00B | $1.10B | $1.28B | -$2.43B | $2.66B | -$649.0M | -$957.0M |
| EPS | $9.09 | $1.11 | $3.04 | $1.97 | $2.17 | $2.56 | -$4.83 | $5.25 | -$1.27 | -$1.75 |
| EPS (Diluted) | $9.01 | $1.08 | $2.97 | $1.93 | $2.13 | $2.53 | -$4.83 | $5.23 | -$1.27 | -$1.75 |
| Shares Outstanding (Diluted) | 551.0 M | 555.0 M | 546.0 M | 519.0 M | 517.0 M | 508.0 M | 504.0 M | 506.0 M | 510.0 M | 513.0 M |
Price
| Price | $25.49 (closing price, November 3, 2026) |
| Market Cap | $13.2B |
| Exchange | NYSE |
| Country | US |
Related companies: ICUI · FMS · DVA · ISRG · 0R29.L · 0R19.L · BDX · 0KW4.L
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BAX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks